
Baseimmune Closes $11.3M Series A to Accelerate AI-Designed Vaccines
Founded in 2019, Baseimmune leverages proprietary deep learning algorithms to predict future mutations of pathogens and design synthetic antigen proteins that can provide broader, longer-lasting immune protection.